Arcellx, Inc.
ACLXNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | $22.3M | $107.9M | $110.3M | — | — |
| Operating income | −$253.1M | −$137.6M | −$89.9M | −$191.3M | −$65.0M |
| Net income | −$228.9M | −$107.3M | −$70.7M | −$188.7M | −$65.0M |
| Total assets | $604.0M | $711.3M | $825.1M | $313.8M | $128.8M |
| Total liabilities | $201.6M | $256.5M | $339.8M | $108.9M | $16.9M |
| Equity | $402.4M | $454.8M | $485.4M | −$205.0M | −$121.5M |
| EPS (diluted) | $-4.07 | $-2.00 | $-1.47 | $-5.19 | $-145.55 |
| Shares out. | 54.9M | 52.8M | 47.8M | 44.1M | 544,210 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1135.6%
- Net margin
- −1027.3%
- Return on equity
- −56.9%
- Return on assets
- −37.9%
- Return on capital (ROCE)
- −50.6%
- Liabilities / assets
- 33.4%
- Debt / equity
- 0.50×
- Book value / share
- $7.32
- Revenue growth (YoY)
- −79.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -0.75distress
- Accruals / assets
- −3.1%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 16, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vestal Point Capital, LpPassive (13G)May 15, 2026
- New Enterprise Associates 15, L.P.Activist (13D)Apr 30, 2026
- Elghandour RamiActivist (13D)Apr 28, 2026
- Gilead Sciences, Inc.Activist (13D)Apr 28, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- T. Rowe Price Investment Management, Inc.Passive (13G)Mar 6, 2026
- Fmr LlcPassive (13G)Mar 6, 2026
- Ra Capital Management, L.P.Passive (13G)Feb 17, 2026
- Paradigm Biocapital Advisors LpPassive (13G)Feb 17, 2026
- Perceptive Advisors LlcPassive (13G)Aug 14, 2025
- Blackrock, Inc.Passive (13G)Apr 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Apr 15, 2026 | 1.8M | 2.5 | -20.7% |
| Mar 31, 2026 | 2.3M | 1.5 | -51.7% |
| Mar 13, 2026 | 4.7M | 3.4 | -18.5% |
| Feb 27, 2026 | 5.8M | 1.0 | -38.0% |
| Feb 13, 2026 | 9.3M | 13.4 | +2.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsApr 28, 2026
- Entered a material agreement · Regulation FD disclosureFeb 23, 2026
- Other material eventDec 8, 2025
- Results of operationsNov 5, 2025
- Results of operationsAug 7, 2025
- Shareholder voteMay 28, 2025
- Other material eventMay 14, 2025
- Results of operationsMay 8, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.